文献速递消化系统肿瘤

立体定向体部放疗联合帕博利珠单抗与曲美替尼对比立体定向体部放疗联合吉西他滨治疗术后局部复发胰腺癌:开放标签、随机对照、2期试验

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2022-01-01

这项开放标签随机对照2期试验纳入170例KRAS突变且PD-L1阳性的术后局部复发胰腺导管腺癌患者,1:1随机接受SBRT联合帕博利珠单抗与曲美替尼或SBRT联合吉西他滨。联合组中位总生存14.9个月 vs 12.8个月(HR 0.69,95%CI 0.51-0.95;p=0.021)。作者认为该联合方案可能成为新治疗选择,需3期试验确认。

要点

  • SBRT联合帕博利珠单抗与曲美替尼组中位总生存14.9个月,SBRT联合吉西他滨组12.8个月(HR 0.69,95%CI 0.51-0.95;p=0.021)。
  • 3-4级不良事件中,转氨酶升高联合组10例(12%)vs 吉西他滨组6例(7%),胆红素升高4例(5%)vs 0例。
  • 严重不良事件联合组19例(22%)vs 吉西他滨组12例(14%),无治疗相关死亡。

核心结论

  • SBRT联合帕博利珠单抗与曲美替尼可能成为术后局部复发胰腺癌患者的新治疗选择。
  • 作者指出需3期试验确认本研究发现。

研究设计与样本

  • 开放标签、随机对照、2期研究,在中国上海海军军医大学附属长海医院招募患者。
  • 纳入标准为年龄18岁及以上、组织学确诊胰腺导管腺癌、KRAS突变、PD-L1免疫组化染色阳性、ECOG体能状态0或1、术后化疗(mFOLFIRINOX或5-氟尿嘧啶)后记录到局部复发。
  • 2016年10月10日至2017年10月28日筛查198例,入组170例,1:1随机分配至SBRT联合帕博利珠单抗与曲美替尼组(n=85)或SBRT联合吉西他滨组(n=85),随机未分层。
  • 主要终点为意向治疗人群的总生存,安全性在至少接受一剂研究治疗的as-treated人群中评估。
  • 试验注册号NCT02704156,现已完成。

主要发现

  • 截至临床截止日期2020年11月30日,中位随访13.1个月(IQR 10.2-17.1)。
  • SBRT联合帕博利珠单抗与曲美替尼组中位总生存14.9个月(12.7-17.1),SBRT联合吉西他滨组12.8个月(95%CI 11.2-14.4),HR 0.69(95%CI 0.51-0.95),p=0.021。
  • 最常见的3或4级不良事件:丙氨酸氨基转移酶或天冬氨酸氨基转移酶升高联合组10例(12%)vs 吉西他滨组6例(7%);血胆红素升高4例(5%)vs 0例;中性粒细胞减少1例(1%)vs 9例(11%);血小板减少1例(1%)vs 4例(5%)。
  • 严重不良事件联合组19例(22%)vs 吉西他滨组12例(14%),无治疗相关死亡。

关键数值与推荐

  • SBRT剂量35-40 Gy分5次;帕博利珠单抗200 mg静脉注射每3周一次;曲美替尼2 mg口服每日一次。
  • 吉西他滨1000 mg/m2静脉注射,21天周期第1天和第8天给药,共8周期。
  • 治疗持续至疾病进展、死亡、不可接受毒性或撤回知情同意。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为SBRT联合帕博利珠单抗与曲美替尼可能成为术后局部复发胰腺癌的新治疗选择,并指出需3期试验确认。

局限性

  • 作者指出需3期试验确认本研究发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is paucity of investigations into immunotherapy or targeted therapy for postoperative locally recurrent pancreatic cancer. We aimed to assess the efficacy of stereotactic body radiotherapy (SBRT) plus pembrolizumab and trametinib in these patients. METHODS: In this open-label, randomised, controlled, phase 2 study, participants were recruited from Changhai Hospital affiliated to the Naval Medical University, Shanghai, China. Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1, Eastern Cooperative Oncology Group performance status of 0 or 1, and documented local recurrence after surgery followed by chemotherapy (mFOLFIRINOX [ie, 5-fluorouracil, oxaliplatin, irinotecan, and folinic acid] or 5-fluorouracil). Eligible participants were randomly assigned (1:1) using an interactive voice or web response system, without stratification, to receive SBRT with doses ranging from 35-40 Gy in five fractions, intravenous pembrolizumab 200 mg once every 3 weeks, and oral trametinib 2 mg once daily or SBRT (same regimen) and intravenous gemcitabine (1000 mg/m2) on day 1 and 8 of a 21-day cycle for eight cycles until disease progression, death, unacceptable toxicity, or consent withdrawal. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the as-treated population in all participants who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02704156, and is now complete. FINDINGS: Between Oct 10, 2016, and Oct 28, 2017, 198 patients were screened, of whom 170 patients were enrolled and randomly assigned to receive SBRT plus pembrolizumab and trametinib (n=85) or SBRT plus gemcitabine (n=85). As of the clinical cutoff date (Nov 30, 2020), median follow-up was 13·1 months (IQR 10·2-17·1). Median overall survival was 14·9 months (12·7-17·1) with SBRT plus pembrolizumab and trametinib and 12·8 months (95% CI 11·2-14·4) with SBRT plus gemcitabine (hazard ratio [HR] 0·69 [95% CI 0·51-0·95]; p=0·021). The most common grade 3 or 4 adverse effects were increased alanine aminotransferase or aspartate aminotransferase (ten [12%] of 85 in SBRT plus pembrolizumab and trametinib group vs six [7%] of 85 in SBRT plus gemcitabine group), increased blood bilirubin (four [5%] vs none), neutropenia (one [1%] vs nine [11%]), and thrombocytopenia (one [1%] vs four [5%]). Serious adverse events were reported by 19 (22%) participants in the SBRT plus pembrolizumab and trametinib group and 12 (14%) in the SBRT plus gemcitabine group. No treatment-related deaths occurred. INTERPRETATION: The combination of SBRT plus pembrolizumab and trametinib could be a novel treatment option for patients with locally recurrent pancreatic cancer after surgery. Phase 3 trials are needed to confirm our findings. FUNDING: Shanghai Shenkang Center and Changhai Hospital. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhu X, Cao Y, Liu W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022. PMID: 35240087. doi:10.1016/S1470-2045(22)00066-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。